CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

Abstract Background This study sought to compare the benefits and safety of agents including Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors, and histone deacetylase (HDAC) inhibitors as second-line treatments for thes...

Full description

Bibliographic Details
Main Authors: Danyang Ji, Yang Luo, Jiayu Wang, Shanshan Chen, Bo Lan, Fei Ma, Binghe Xu, Ying Fan
Format: Article
Language:English
Published: BMC 2023-08-01
Series:BMC Cancer
Subjects:
CDK4/6 inhibitors
Hormone receptor-positive
Metastatic breast cancer
Network meta-analysis
Online Access:https://doi.org/10.1186/s12885-023-11290-7

Internet

https://doi.org/10.1186/s12885-023-11290-7

Similar Items